Economic burden of seasonal influenza in the United States.

BACKGROUND Seasonal influenza is responsible for a large disease and economic burden. Despite the expanding recommendation of influenza vaccination, influenza has continued to be a major public health concern in the United States (U.S.). To evaluate influenza prevention strategies it is important that policy makers have current estimates of the economic burden of influenza. OBJECTIVE To provide an updated estimate of the average annual economic burden of seasonal influenza in the U.S. population in the presence of vaccination efforts. METHODS We evaluated estimates of age-specific influenza-attributable outcomes (ill-non medically attended, office-based outpatient visit, emergency department visits, hospitalizations and death) and associated productivity loss. Health outcome rates were applied to the 2015 U.S. population and multiplied by the relevant estimated unit costs for each outcome. We evaluated both direct healthcare costs and indirect costs (absenteeism from paid employment) reporting results from both a healthcare system and societal perspective. Results were presented in five age groups (<5 years, 5-17 years, 18-49 years, 50-64 years and ≥65 years of age). RESULTS The estimated average annual total economic burden of influenza to the healthcare system and society was $11.2 billion ($6.3-$25.3 billion). Direct medical costs were estimated to be $3.2 billion ($1.5-$11.7 billion) and indirect costs $8.0 billion ($4.8-$13.6 billion). These total costs were based on the estimated average numbers of (1) ill-non medically attended patients (21.6 million), (2) office-based outpatient visits (3.7 million), (3) emergency department visit (0.65 million) (4) hospitalizations (247.0 thousand), (5) deaths (36.3 thousand) and (6) days of productivity lost (20.1 million). CONCLUSIONS This study provides an updated estimate of the total economic burden of influenza in the U.S. Although we found a lower total cost than previously estimated, our results confirm that influenza is responsible for a substantial economic burden in the U.S.

[1]  M. Postma,et al.  Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in the United States. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[2]  M. Biggerstaff,et al.  Net Costs Due to Seasonal Influenza Vaccination — United States, 2005–2009 , 2015, PloS one.

[3]  M. Meltzer,et al.  The economic impact of pandemic influenza in the United States: priorities for intervention. , 1999, Emerging infectious diseases.

[4]  Kristine A. Smith,et al.  Cost Collection and Analysis for Health Economic Evaluation , 2013, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[5]  C. Viboud,et al.  Influenza-attributable mortality in Australians aged more than 50 years: a comparison of different modelling approaches , 2009, Epidemiology and Infection.

[6]  Carrie Reed,et al.  Seasonal Incidence of Symptomatic Influenza in the United States , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  W. Brouwer,et al.  Productivity Costs in Economic Evaluations: Past, Present, Future , 2013, PharmacoEconomics.

[8]  Keiji Fukuda,et al.  Influenza-associated hospitalizations in the United States. , 2004, JAMA.

[9]  K. Mandl,et al.  Relative Impact of Influenza and Respiratory Syncytial Virus in Young Children , 2009, Pediatrics.

[10]  Robert J. Taylor,et al.  Model estimates of the burden of outpatient visits attributable to influenza in the United States , 2016, BMC Infectious Diseases.

[11]  L. Simonsen The global impact of influenza on morbidity and mortality. , 1999, Vaccine.

[12]  Hong Zhou,et al.  Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  C. Bridges,et al.  Indirect, out-of-pocket and medical costs from influenza-related illness in young children. , 2012, Vaccine.

[14]  K. Edwards,et al.  Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. , 2002, The Journal of infectious diseases.

[15]  S. Karve,et al.  Employer-incurred health care costs and productivity losses associated with influenza , 2013, Human vaccines & immunotherapeutics.

[16]  P. Buck,et al.  A Retrospective Cohort Study of the Incidence, Health Care Resource Utilization and Costs of International Classification of Diseases, Clinical Modification, 9th Revision Diagnosed Influenza and Related Complications in US Children. , 2017, The Pediatric infectious disease journal.

[17]  M. Taljaard,et al.  Comparative effectiveness of high-dose versus standard-dose influenza vaccination on numbers of US nursing home residents admitted to hospital: a cluster-randomised trial. , 2017, The Lancet. Respiratory medicine.

[18]  Ivo M Foppa,et al.  Estimated paediatric mortality associated with influenza virus infections, United States, 2003–2010 , 2014, Epidemiology and Infection.

[19]  L. Grohskopf,et al.  Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices--United States, 2013-2014. , 2013, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[20]  Joseph E. Aldy,et al.  The Value of a Statistical Life: A Critical Review of Market Estimates Throughout the World , 2003 .

[21]  A. Shorr,et al.  Understanding cost-effectiveness. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[22]  C. Bridges,et al.  The annual impact of seasonal influenza in the US: measuring disease burden and costs. , 2007, Vaccine.

[23]  M. Drummond,et al.  Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes , 1988 .

[24]  A. Monto Epidemiology of influenza. , 2008, Vaccine.

[25]  Steve Di Lonardo,et al.  Incidence of medically attended influenza during pandemic and post-pandemic seasons through the Influenza Incidence Surveillance Project, 2009-13. , 2015, The Lancet. Respiratory medicine.

[26]  B. Sander,et al.  Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[27]  C. Viboud,et al.  Age- and sex-related risk factors for influenza-associated mortality in the United States between 1997-2007. , 2014, American journal of epidemiology.

[28]  B. Zierler,et al.  The principles of cost-effectiveness analysis and their application. , 2003, Journal of vascular surgery.

[29]  G. Sanders,et al.  Cost-Effectiveness in Health and Medicine , 2016 .

[30]  Thomas MaCurdy,et al.  Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. , 2015, The Lancet. Infectious diseases.

[31]  Lin Yang,et al.  Influenza-Associated Hospitalization in a Subtropical City , 2006, PLoS medicine.

[32]  Kurt V. Krueger,et al.  Economic Productivity by Age and Sex: 2007 Estimates for the United States , 2009, Medical care.

[33]  M. Lichtveld,et al.  Effects of antiviral treatment on influenza-related complications over four influenza seasons: 2006–2010 , 2016, Current medical research and opinion.

[34]  A. Monto,et al.  Illness Severity and Work Productivity Loss Among Working Adults With Medically Attended Acute Respiratory Illnesses: US Influenza Vaccine Effectiveness Network 2012-2013. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  A. Chit,et al.  The Annual Burden of Seasonal Influenza in the US Veterans Affairs Population , 2017, PloS one.